Kathy Borden of the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) and her collaborators has identified a mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse. Kathy Borden is a Principal Investigator at IRIC and a professor at the university's Department of Pathology and Cell Biology. The development of drug resistance is one of the main problems in clinical ...
Read More
You have just read an article categorized health
titled Major Discovery on the Mechanism of Drug Resistance in Acute Myeloid Leukemia.
Written by:
editor -
Sunday, June 1, 2014
There are currently no comments for "Major Discovery on the Mechanism of Drug Resistance in Acute Myeloid Leukemia"
Post a Comment